D.A. Wallach

World-class Healthcare: Investing in Biomedical Innovation

Tanisha Carino, Christopher Hite, Bryan Johnson, Sean Parker, D.A. Wallach

Moderated by Dr. Tanisha Carino in Abu Dhabi, this session analyzed the convergence of global biomedical innovation and market dynamics, highlighted by the historic $92 billion Bristol-Myers Squibb acquisition of Celgene as a catalyst for pipeline stability. The discussion detailed how falling hard science costs and platforms like Ginkgo Bioworks are compressing development timelines, while investment strategies increasingly favor foundational tools over singular disease treatments to address the translational gap between academic research and commercial viability. Despite concerns regarding venture capital concentration in oncology and systemic US healthcare incentives, the event projected that long-term pricing decreases and extended lifespans could emerge from global regulatory evolution and the integration of AI-driven data collection.